Evolving evidence-based recommendations in T2D

This module summarises recent changes to global diabetes, cardiovascular disease, heart failure and kidney disease guidelines and updated label indications as a result of cardiovascular outcome trials (CVOTs) and cardiorenal trials.

Evolving evidence-based recommendations in T2D
Rate this content
  • Evolving evidence-based recommendations in T2D
  • Evolving evidence-based recommendations in T2D
  • Patients with T2D have multiple risk factors that contribute to Cardio-Renal-Metabolic (CRM) diseases
  • The cardiovascular-renal-metabolic aspects of T2D should be addressed by a holistic approach across the continuum
  • Reductions in CV, HF and kidney outcomes observed with SGLT2 inhibitors in patients with T2D
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go